Globus Medical (GMED)
(Real Time Quote from BATS)
$71.82 USD
-0.18 (-0.25%)
Updated Jul 16, 2024 02:32 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GMED 71.82 -0.18(-0.25%)
Will GMED be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GMED based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMED
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Integra's (IART) New Site to Produce Recalled Tissue Products
GMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Keep Chemed (CHE) Stock in Your Portfolio Now?
Here's Why Globus Medical (GMED) is a Strong Growth Stock
Here's Why Globus Medical (GMED) is a Strong Growth Stock
Other News for GMED
Buy Rating Affirmed: Globus Medical’s Strategic Entry into Joint Reconstruction Robotics and Growth Potential
Globus Medical: Hold Rating Amid Modest Short-Term Impact from ExcelsiusFlex Approval
First Week of August 16th Options Trading For Globus Medical (GMED)
Globus Medical (GMED) Gets a Buy from RBC Capital
Orthofix appoints McPherron as President of Global Operations, Quality